Use the Back button in your browser to see the other results of your search or to select another record.
Effects of 12-week exercise program on enzyme activity of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in female patients with postmenopausal osteoporosis: a randomized control study |
Filipovic T, Gopcevic K, Dimitrijevic S, Hrkovic M, Backovic A, Lazovic M |
BioMed Research International 2020;(9758289):Epub |
clinical trial |
6/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
BACKGROUND: Osteoporosis is a disease characterized by decreased bone density and destruction of bone microarchitecture. Indicators for altered bone homeostasis are changes in the serum level of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). The purpose of the current study was to evaluate the effect of a 12-week exercise program on enzyme activity of serum MMP-9 and TIMP-1 in postmenopausal osteoporotic patients. MATERIALS AND METHODS: Participants were randomized in two groups: exercise (EG) (N = 37) and control (CG) (N = 37) and control (CG). RESULTS: Significant differences between pretreatment and posttreatment enzyme activities of serum MMP-9 (p = 0.009), TIMP-1 (p = 0.009), TIMP-1 (p = 0.009), TIMP-1 (. CONCLUSION: Our results suggest that a 12-week exercise program has an influence on enzyme activity of serum MMP-9, revealing a possible role of MMPs in initiating training-specific adaptation. Although measurements of circulating MMP-9 and TIMP-1 allowed us to detect effects of exercise, as of today, they have no real role in the diagnosis of osteoporosis and/or follow-up of osteoporotic patient's response to treatment. MMP-9 might be used as an important prognostic marker for the evaluation of patient's response to exercise. Larger-randomized controlled studies need to be performed to expand this area of knowledge. (This trial is registered with trial registration number NCT03816449).
|